Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?

Publisher： Karger

E-ISSN： 1662-6575|9|1|273-279

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.1, 2016-05, pp. : 273-279

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 352-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 4, 2018-02 ,pp. : 534-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 188-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cytokeratin‐positive primary effusion lymphoma: a diagnostic challenge

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 9-9

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunoliposomal systems targeting primary effusion lymphoma: in vitro study

By Ruozi Barbara   Riva Giovanni   Belletti Daniela   Tosi Giovanni   Barozzi Patrizia   Luppi Mario   Forni Flavio   Vandelli Maria Angela  

Nanomedicine, Vol. 5, Iss. 7, 2010-09 ,pp. : 1051-1064

Future Medicine

Access to resources Recommend Favorite